105 related articles for article (PubMed ID: 8884220)
1. Antiproliferative and receptor binding properties of alpha- and beta-casomorphins in the T47D human breast cancer cell line.
Hatzoglou A; Bakogeorgou E; Hatzoglou C; Martin PM; Castanas E
Eur J Pharmacol; 1996 Aug; 310(2-3):217-23. PubMed ID: 8884220
[TBL] [Abstract][Full Text] [Related]
2. The antiproliferative effect of opioid receptor agonists on the T47D human breast cancer cell line, is partially mediated through opioid receptors.
Hatzoglou A; Bakogeorgou E; Castanas E
Eur J Pharmacol; 1996 Jan; 296(2):199-207. PubMed ID: 8838457
[TBL] [Abstract][Full Text] [Related]
3. Opioid alkaloids and casomorphin peptides decrease the proliferation of prostatic cancer cell lines (LNCaP, PC3 and DU145) through a partial interaction with opioid receptors.
Kampa M; Bakogeorgou E; Hatzoglou A; Damianaki A; Martin PM; Castanas E
Eur J Pharmacol; 1997 Sep; 335(2-3):255-65. PubMed ID: 9369381
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel opioid peptide (Tyr-Val-Pro-Phe-Pro) derived from human alpha S1 casein (alpha S1-casomorphin, and alpha S1-casomorphin amide).
Kampa M; Loukas S; Hatzoglou A; Martin P; Martin PM; Castanas E
Biochem J; 1996 Nov; 319 ( Pt 3)(Pt 3):903-8. PubMed ID: 8920997
[TBL] [Abstract][Full Text] [Related]
5. Beta-casomorphin-5 stimulates neurite outgrowth in a mouse neuroblastoma cell line (Neuro-2a).
Sakaguchi M; Murayama K; Yabe K; Satoh M; Takeuchi M; Matsumura E
Neurosci Lett; 1998 Jul; 251(2):97-100. PubMed ID: 9718983
[TBL] [Abstract][Full Text] [Related]
6. Opioid agonists modify breast cancer cell proliferation by blocking cells to the G2/M phase of the cycle: involvement of cytoskeletal elements.
Panagiotou S; Bakogeorgou E; Papakonstanti E; Hatzoglou A; Wallet F; Dussert C; Stournaras C; Martin PM; Castanas E
J Cell Biochem; 1999 May; 73(2):204-11. PubMed ID: 10227383
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of opioid and somatostatin binding sites in the opossum kidney (OK) cell line and their effect on growth.
Hatzoglou A; Bakogeorgou E; Papakonstanti E; Stournaras C; Emmanouel DS; Castanas E
J Cell Biochem; 1996 Dec; 63(4):410-21. PubMed ID: 8978457
[TBL] [Abstract][Full Text] [Related]
8. Modulation of the estrogen-regulated proteins cathepsin D and pS2 by opioid agonists in hormone-sensitive breast cancer cell lines (MCF7 and T47D): evidence for an interaction between the two systems.
Panagiotou S; Hatzoglou A; Calvo F; Martin PM; Castanas E
J Cell Biochem; 1998 Dec; 71(3):416-28. PubMed ID: 9831078
[TBL] [Abstract][Full Text] [Related]
9. Milk bioactive peptides and beta-casomorphins induce mucus release in rat jejunum.
Trompette A; Claustre J; Caillon F; Jourdan G; Chayvialle JA; Plaisancié P
J Nutr; 2003 Nov; 133(11):3499-503. PubMed ID: 14608064
[TBL] [Abstract][Full Text] [Related]
10. Opioids are non-competitive inhibitors of nitric oxide synthase in T47D human breast cancer cells.
Kampa M; Hatzoglou A; Notas G; Niniraki M; Kouroumalis E; Castanas E
Cell Death Differ; 2001 Sep; 8(9):943-52. PubMed ID: 11526449
[TBL] [Abstract][Full Text] [Related]
11. Morphine cross-reacts with somatostatin receptor SSTR2 in the T47D human breast cancer cell line and decreases cell growth.
Hatzoglou A; Ouafik L; Bakogeorgou E; Thermos K; Castanas E
Cancer Res; 1995 Dec; 55(23):5632-6. PubMed ID: 7585646
[TBL] [Abstract][Full Text] [Related]
12. Adrenal medullary opiate receptors. Pharmacological characterization in bovine adrenal medulla and a human pheochromocytoma.
Castanas E; Giraud P; Audigier Y; Drissi R; Boudouresque F; Conte-Devolx B; Oliver C
Mol Pharmacol; 1984 Jan; 25(1):38-45. PubMed ID: 6323951
[TBL] [Abstract][Full Text] [Related]
13. Differential antagonism of opioid delta antinociception by [D-Ala2,Leu5,Cys6]enkephalin and naltrindole 5'-isothiocyanate: evidence for delta receptor subtypes.
Jiang Q; Takemori AE; Sultana M; Portoghese PS; Bowen WD; Mosberg HI; Porreca F
J Pharmacol Exp Ther; 1991 Jun; 257(3):1069-75. PubMed ID: 1646319
[TBL] [Abstract][Full Text] [Related]
14. Studies on mu and delta opioid receptor selectivity utilizing chimeric and site-mutagenized receptors.
Wang WW; Shahrestanifar M; Jin J; Howells RD
Proc Natl Acad Sci U S A; 1995 Dec; 92(26):12436-40. PubMed ID: 8618916
[TBL] [Abstract][Full Text] [Related]
15. Opioid regulation of the mouse delta-opioid receptor expressed in human embryonic kidney 293 cells.
Bot G; Blake AD; Li S; Reisine T
Mol Pharmacol; 1997 Aug; 52(2):272-81. PubMed ID: 9271350
[TBL] [Abstract][Full Text] [Related]
16. Decrease in delta-opioid receptor density in rat brain after chronic [D-Ala2,D-Leu5]enkephalin treatment.
Tao PL; Chang LR; Law PY; Loh HH
Brain Res; 1988 Oct; 462(2):313-20. PubMed ID: 2847851
[TBL] [Abstract][Full Text] [Related]
17. delta-Opioid receptor binding in mouse brain: evidence for heterogeneous binding sites.
Sofuoglu M; Portoghese PS; Takemori AE
Eur J Pharmacol; 1992 Jun; 216(2):273-7. PubMed ID: 1327813
[TBL] [Abstract][Full Text] [Related]
18. Mu opioid receptors participate in the excitatory effect of opiates in the hippocampal slice.
Bostock E; Dingledine R; Xu G; Chang KJ
J Pharmacol Exp Ther; 1984 Dec; 231(3):512-7. PubMed ID: 6094789
[TBL] [Abstract][Full Text] [Related]
19. Determination of the receptor selectivity of opioid agonists in the guinea-pig ileum and mouse vas deferens by use of beta-funaltrexamine.
Hayes AG; Sheehan MJ; Tyers MB
Br J Pharmacol; 1985 Dec; 86(4):899-904. PubMed ID: 3000501
[TBL] [Abstract][Full Text] [Related]
20. Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes.
Sofuoglu M; Portoghese PS; Takemori AE
J Pharmacol Exp Ther; 1991 May; 257(2):676-80. PubMed ID: 1851833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
